Allan Hackshaw

32.2k total citations · 6 hit papers
202 papers, 10.7k citations indexed

About

Allan Hackshaw is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Allan Hackshaw has authored 202 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 34 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Allan Hackshaw's work include Prenatal Screening and Diagnostics (30 papers), Lung Cancer Treatments and Mutations (25 papers) and Global Cancer Incidence and Screening (24 papers). Allan Hackshaw is often cited by papers focused on Prenatal Screening and Diagnostics (30 papers), Lung Cancer Treatments and Mutations (25 papers) and Global Cancer Incidence and Screening (24 papers). Allan Hackshaw collaborates with scholars based in United Kingdom, United States and France. Allan Hackshaw's co-authors include Nicholas Wald, M R Law, Charles H. Rodeck, Sadie Boniface, E. Anne MacGregor, Hilary Watt, Jocelyn Walters, Lyn S. Chitty, Anne Kennard and Jin-Ling Tang and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Allan Hackshaw

188 papers receiving 10.2k citations

Hit Papers

First-Trimester or Second-Trimester Screening, or Both, f... 1997 2026 2006 2016 2005 1997 2004 1997 2011 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome
    2005 718 citations Fergal D. Malone, Jacob A. Canick et al. profile →
  2. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect
    1997 525 citations Allan Hackshaw et al. profile →
  3. Tobacco and Cancer: Recent Epidemiological Evidence
    2004 500 citations Allan Hackshaw et al. profile →
  4. The accumulated evidence on lung cancer and environmental tobacco smoke
    1997 500 citations Allan Hackshaw, Nicholas Wald et al. profile →
  5. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls
    2011 485 citations Allan Hackshaw et al. profile →
  6. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports
    2018 376 citations Allan Hackshaw et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allan Hackshaw United Kingdom 50 3.4k 2.3k 1.9k 1.7k 1.7k 202 10.7k
Glenn E. Palomaki United States 52 6.3k 1.8× 892 0.4× 1.7k 0.9× 1.1k 0.6× 2.0k 1.1× 255 14.2k
Angela C Webster Australia 63 1.1k 0.3× 2.5k 1.1× 3.0k 1.6× 1.9k 1.1× 762 0.4× 298 15.6k
Mark R. Conaway United States 62 1.4k 0.4× 2.3k 1.0× 1.8k 1.0× 2.3k 1.3× 407 0.2× 280 12.2k
Chien‐Wen Tseng United States 58 1.2k 0.3× 3.5k 1.6× 1.8k 0.9× 2.4k 1.4× 491 0.3× 130 14.8k
Olaf M. Dekkers Netherlands 80 917 0.3× 1.8k 0.8× 6.7k 3.6× 1.8k 1.0× 1.6k 0.9× 398 22.9k
Scott D. Grosse United States 62 2.9k 0.9× 451 0.2× 1.2k 0.6× 1.7k 1.0× 1.2k 0.7× 262 13.3k
John W. Epling United States 53 875 0.3× 3.6k 1.6× 1.9k 1.0× 2.1k 1.2× 474 0.3× 119 13.1k
Matthew M. Zack United States 54 1.6k 0.5× 1.8k 0.8× 1.6k 0.8× 746 0.4× 278 0.2× 173 11.3k
Anders Ekbom Sweden 66 2.0k 0.6× 4.6k 2.0× 4.6k 2.5× 2.0k 1.2× 420 0.2× 273 20.1k
Joan C. Lo United States 48 914 0.3× 1.6k 0.7× 1.4k 0.8× 326 0.2× 1.7k 1.0× 197 10.1k

Countries citing papers authored by Allan Hackshaw

Since Specialization
Citations

This map shows the geographic impact of Allan Hackshaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan Hackshaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan Hackshaw more than expected).

Fields of papers citing papers by Allan Hackshaw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan Hackshaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan Hackshaw. The network helps show where Allan Hackshaw may publish in the future.

Co-authorship network of co-authors of Allan Hackshaw

This figure shows the co-authorship network connecting the top 25 collaborators of Allan Hackshaw. A scholar is included among the top collaborators of Allan Hackshaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan Hackshaw. Allan Hackshaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hackshaw, Allan, Otto Fajardo, Urania Dafni, et al.. (2024). Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting. JCO Precision Oncology. 8(8). e2300334–e2300334.
2.
3.
Matza, Louis S., Eric T. Fung, Sam M. Janes, et al.. (2024). Health State Utilities Associated with False-Positive Cancer Screening Results. PharmacoEconomics - Open. 8(2). 263–276. 2 indexed citations
4.
Anderson, A. W., Cristina Visintin, Antonis C. Antoniou, et al.. (2024). Risk stratification in breast screening workshop. BMC Proceedings. 18(S19). 22–22. 1 indexed citations
5.
Hiley, Crispin T., T. Ahmad, Matthew Krebs, et al.. (2023). LBA72 DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC. Annals of Oncology. 34. S1314–S1314.
6.
Horgan, Denis, Dario Trapani, Umberto Malapelle, et al.. (2023). Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine. Diagnosis. 10(4). 356–362. 2 indexed citations
7.
Hackshaw, Allan, Kate Newbold, Matthew Beasley, et al.. (2023). 2212MO Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients?. Annals of Oncology. 34. S1142–S1142. 3 indexed citations
8.
Rockall, Andrea, Tara Barwick, William Wilson, et al.. (2021). Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma. Clinical Cancer Research. 27(23). 6457–6466. 15 indexed citations
9.
Laszlo, Helga, Edward Seward, Ruth M Ayling, et al.. (2021). Faecal immunochemical test for patients with ‘high-risk’ bowel symptoms: a large prospective cohort study and updated literature review. British Journal of Cancer. 126(5). 736–743. 16 indexed citations
10.
McCourt, Orla, Małgorzata Heinrich, Rebecca J. Beeken, et al.. (2020). The adapted Zelen was a feasible design to trial exercise in myeloma survivors. Journal of Clinical Epidemiology. 125. 76–83. 5 indexed citations
11.
Fennell, Dean A., Sarah Danson, Penella J. Woll, et al.. (2020). Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial. Clinical Cancer Research. 26(18). 4748–4755. 13 indexed citations
12.
Khan, Iftekhar, Stephen Morris, Allan Hackshaw, & Siow Ming Lee. (2015). Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open. 5(7). e006733–e006733. 14 indexed citations
13.
Ledermann, Jonathan A., Allan Hackshaw, Gordon C. Jayson, et al.. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology. 29(28). 3798–3804. 164 indexed citations
14.
Hackshaw, Allan, Sy Ha, Sharon Forsyth, et al.. (2011). Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer. Journal of Clinical Oncology. 29(13). 1657–1663. 68 indexed citations
15.
16.
Lee, Siow Ming, Penella J. Woll, M. Hatton, et al.. (2007). A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC). UCL Discovery (University College London). 6 indexed citations
17.
Wong, Angela, et al.. (2007). Large-scale prospective study reveals novel risk factors for Barrett's oesophagus. UCL Discovery (University College London). 1 indexed citations
18.
MacGregor, E. Anne, Alison Frith, Jayne E. Ellis, Laurence Aspinall, & Allan Hackshaw. (2006). Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 67(12). 2154–2158. 231 indexed citations
19.
Malone, Fergal D., Jacob A. Canick, Robert H. Ball, et al.. (2006). First-Trimester or Second-Trimester Screening, or Both, for Down???s Syndrome. Obstetrical & Gynecological Survey. 61(4). 226–228. 102 indexed citations
20.
Malone, Fergal D., Nicholas Wald, Jacob A. Canick, et al.. (2003). Use of overall population, center-specific, and sonographer-specific nuchal translucency medians in down syndrome screening: which is best? (Results from the faster trial). American Journal of Obstetrics and Gynecology. 189(6). S232–S232. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Glenn E. Palomaki Breakdown of academic impact, for papers by Angela C Webster Breakdown of academic impact, for papers by Mark R. Conaway Breakdown of academic impact, for papers by Chien‐Wen Tseng Breakdown of academic impact, for papers by Olaf M. Dekkers Breakdown of academic impact, for papers by Scott D. Grosse Breakdown of academic impact, for papers by John W. Epling Breakdown of academic impact, for papers by Matthew M. Zack Breakdown of academic impact, for papers by Anders Ekbom Breakdown of academic impact, for papers by Joan C. Lo
Rankless by CCL
2026